Abstract��OBJECTIVE To analyze the mechanism of clinical hold in USA and to provide reference and enlightenment for clinical trial review process reform in China. METHODS Analyzed the regulation, review process, reasons and impacts of drug clinical hold in USA and compared with clinical trial system in China, then provided advice for our country. RESULTS AND CONCLUSION FDA review IND by implied license process within only 30 d, and may permit the clinical trials begin as early as possible, the clinical trial could be imposed on hold, and the hold could also be lifted or transfer into inactive status, thus protect the health and rights of subjects to the largest extent, and in the same time improved the review efficiency. It is necessary and feasible that clinical hold is introduced into clinical trial system in our country.
Ԭ��, ����. ����ҩ���ٴ�������ͣ�����о�[J]. �й�ҩѧ��־, 2017, 52(9): 787-792.
YUAN Li, YANG Yue. Research on Mechanism of Drug Clinical Hold in USA. Chinese Pharmaceutical Journal, 2017, 52(9): 787-792.
BARTON HUTT P. The Impact of Regulation and Reimbursement on Pharmaceutical Innovation[EB/OL]. (1991-1-1) [2016-9-5]. http://www. ncbi. nlm. nih. gov/books/NBK234312/.
[2]
HOLBEIN B M E. Understanding FDA regulatory requirements for investigational new drug application for sponsor-investigators [J]. J Investig Med, 2009,57(6):689-695.
[3]
US. Food and Drug Administration. MAPP 6030. 1-IND Process and Review Procedures (Including Clinical Holds) [EB/OL]. (1998-5-1) [2016-8-15]. http://www. fda. gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/ucm082022. pdf.
[4]
US. Food and Drug Administration. Guidance for Industry:Submitting and Reviewing Complete Responses to Clinical Holds[EB/OL]. (2016-1-15) [2016-8-20]. http://www. fda. gov/downloads/RegulatoryInformation/Guidances/ucm127538. pdf.
[5]
US. Food and Drug Administration. Code of Federal Regulations Title 21: clinical holds and requests for modification. Sec. 312. 42. [EB/OL] (2016-4-1) [2016-8-19]. http://www. accessdata. fda. gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm.
[6]
US. Food and Drug Administration. SOPP 8201:Administrative Processing of Clinical Holds for Investigational New Drug Application[EB/OL]. (2014-5-19) [2016-8-22]. http://www. fda. gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ProceduresSOPPs/UCM399584. pdf.
[7]
US. Food and Drug Administration. IND Application Procedures: Clinical Hold [EB/OL]. (2015-10-9)[2016-08-19]. http://www. fda. gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/ucm362971. htm.
[8]
LAPTEVA L, PARISER A R. Investigational new drug applications: a 1-year pilot study on rates and reasons for clinical hold [J]. J Investig Med, 2016,64(2):376-382.
[9]
BOUDES P F. An analysis of US food and drug administration clinical hold orders for drug and bioligics: a prospective study between 2008 and 2014[J]. Pharm Med,2015,29(4):203-209.
2017, Vol. 52 
